Zuga Matt's Form 4 filing
Acumen Pharmaceuticals, Inc. (ABOS) · filed Jan 7, 2026
- Accession no.
- 0001628280-26-001265
- Filed
- Jan 7, 2026
- Trade date
- Jan 5-7, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions. Open-market sales total $29.5K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Zuga MattCIK 0001790214 | Officer (CFO & Chief Business Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 5, 2026 | Common Stock | SSaleDisposed | −4,000 | $1.96F2 | −$7,840 | 227,744 | Direct | |
| Jan 6, 2026 | Common Stock | SSaleDisposed | −5,100 | $1.97F3 | −$10,047 | 222,644 | Direct | |
| Jan 7, 2026 | Common Stock | SSaleDisposed | −4,105 | $2.00F4 | −$8,210 | 218,539 | Direct | |
| Jan 7, 2026 | Common Stock | SSaleDisposed | −1,700 | $1.99F6 | −$3,383 | 216,839 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9100 to $1.9750. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9400 to $1.9900. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9500 to $2.0400. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F6
The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9600 to $2.0100. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.